KALV · CIK 0001348911
What KalVista Pharmaceuticals, Inc. told the SEC could break it.
KalVista's disclosures center on its dependence on a single, newly launched product — EKTERLY (sebetralstat), FDA-approved in July 2025 — to generate revenue against a $653.2 million accumulated deficit and no prior product sales. That future revenue is already partly encumbered and shared: it sold sebetralstat royalty rights to DRI for $100 million (with an optional payment that would raise DRI's royalty rate), and ex-U.S. sales depend on collaborators like Kaken in Japan, over whom it has limited control. It also flags drug-pricing pressure abroad, where cost-containment in Europe, Canada and elsewhere keeps prices well below U.S. levels.
4 self-disclosed vulnerabilities, pulled from its own filings, each in the company’s words, with the source. This is the risk register almost nobody reads.
In its own words
What could break it.
Other disclosures
- dependence on collaborators (e.g., Kaken) for ex-US commercializationmedium
KalVista has limited control over the resources its collaborators (such as Kaken in Japan) dedicate to developing or commercializing sebetralstat, so its ex-US revenue depends on partners' performance.
“ontrol over the amount and timing of resources that our collaborators dedicate to the development or commercialization of sebetralstat or any other product candidates. Moreover, our ability to generate revenues from these arrangements will depend on our collaborators' abilities to successfully perform the functions assigned to them in these arrangements.”
SEC filing →As of 2025 - single-product dependence on EKTERLY (sebetralstat); $653.2M deficitmedium
KalVista's future revenue depends primarily on successfully commercializing its single approved product, EKTERLY (sebetralstat, FDA-approved July 2025), against a $653.2M accumulated deficit and no historical product revenue.
“The success of our business, including our ability to generate revenue from product sales in the future, will primarily depend on the successful commercialization of EKTERLY (sebetralstat) in the U.S. as well as in other jurisdictions, if approved, and the successful development, regulatory approval and commercialization of our other product candidates”
SEC filing →As of 2025
Liquidity & debt
- DRI royalty-monetization obligations on sebetralstat salesmedium
KalVista sold sebetralstat royalty rights to DRI ($100M + $22M optional post-approval payment); electing the optional payment raises DRI's royalty rate on net sales up to $500M from 5% to 6%, encumbering future product revenue.
“If the Subsidiary chooses to receive this optional payment, the royalty rate on net sales up to and including $500 million will increase from 5.00% to 6.00%, and the sales-based milestone amount will increase from $50.0 million to $57.0 million.”
SEC filing →As of 2025
Regulatory & policy
- drug-pricing controls & cost-containment (Europe, Canada)medium
Cost-containment and price-control mechanisms in Europe, Canada and other countries pressure pricing and usage of KalVista's product, where prices are typically far below U.S. levels.
“we believe the increasing emphasis on cost-containment initiatives in Europe, Canada, and other countries has and will continue to put pressure on the pricing and usage of our product candidates.”
SEC filing →As of 2025
The hidden graph
Who it depends on, and who depends on it.
Relationships surfaced from filings, including ones disclosed by the other side, which is how the non-obvious ones come to light.
Its customers
Kaken Pharmaceutical Co., Ltd.
“The Company is responsible for obtaining and maintaining all regulatory approvals, performing regulatory submissions for the Licensed Product in Japan and supplying the Licensed Product to Kaken. The Company retains manufacturing rights for the Licensed Product”
Cited →
In the MyPRIA app, this is checked against the companies you actually own.
← World Watch